Aerobiotix has bagged a group purchasing contract to supply its patented Illuvia ultraviolet air disinfection products to health care improvement company Premier’s member hospitals.

Premier unites an alliance of about 3,900 hospitals and health system as well as 150,000 other provider organisations in the US.

Aerobiotix Illuvia ultraviolet air disinfection systems work constantly in occupied spaces to slash environmental pathogen levels, due to which there is minimal workflow impact.

Besides disinfecting, the deployable systems sense air to give real-time feedback of air quality indicators to hospital staff.

Hospitals using Aerobiotix ultraviolet air disinfection systems have seen reductions in air microbial levels more than 50%.

Aerobiotix said that its technologies have been proven in peer-reviewed studies to greatly reduce air microbial levels in multiple critical health care settings, including operating rooms.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Aerobiotix chief executive David Kirschman said: “Killing pathogens in the environment before they gain access to patients has always been the ideal strategy to prevent hospital acquired infections. With Aerobiotix, technology is finally catching up with this ideal.

“Contracting with Premier provides its members with efficient access to our technology, shortening the cycle between needs and interventions.”

The agreement will come into force from 1 February 2018.